Objective. To review the pathophysiologic rationale and therapeutic applications of inhibiting angiogenesis in solid tumor growth.
Data Sources. A MEDLINE search of articles published from 1985 to 1995 and a CancerLit search of articles published from 1988 to 1995, using the MESH heading "neovascularization" and text words "angiogenesis" and "antiangiogenesis." References listed in identified publications were reviewed for additional pertinent literature.
Study Selection. All human trials evaluating angiogenesis inhibitors in malignant disease and pre- clinical trials that illustrate potential mechanisms of action of such agents were included.
Data Synthesis. Angiogenesis, the formation of new blood vessels, is necessary for the development of significant solid tumor growth. Inhibition of angio genesis is a unique mechanism of antineoplastic ther apy that does not use traditional cytotoxic actions. Four investigational antiangiogenic agents are cur rently being evaluated in phase I and II trials. Poten tially beneficial applications of angiogenesis inhibitors include suppression of occult and premalignant le sions, symptomatic control of angiogenesis-depen dent malignancies, and combination therapy with traditional antineoplastic agents.
Conclusion. Inhibition of angiogenesis is a new pharmacologic strategy that may prove useful in controlling malignant growth. A number of agents with antiangiogenic activity have been developed, and further study of these drugs will define their role in antineoplastic therapy.
Dusseau JW, Hutchins PM, Malbasa DSStimulation of angiogenesis by adenosine on the chick chorioallantoic membrane . Circ Res.1986;59:163-170.
11.
Liu MM, Wang DL, Liu CYInteractions between fibrin, collagen and endothelial cells in angiogenesis . Adv Exp Med Biol. 1990;281:319-331.
12.
Brooks PC, Clark Raf, Cheresh DARequirement of vascular integrin αvβ3 for angiogenesis . Science.1994;264:569-571.
13.
Sunderkotter C., Steinbrink K., Goebeler M., Bhardwaj R., Sorg C.Macrophages and angiogenesis. J Leukoc Biol.1994;55:410-422.
14.
Ausprunk DH , Folkman J.Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis . Microvasc Res.1977;14:53-65.
15.
Denekamp J.Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol.1993;66:181-196.
16.
Sillman F., Boyce J., Fruchter R.The significance of atypical vessels and neovascularization in cervical neoplasia . Am J Obstet Gynecol.1981;139:154-159.
17.
Nguyen M., Watanabe H., Budson AE, Richie JP, Hayes DF, Folkman J.Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst. 1994;86:356-360.
18.
Fajardo LF, Kwan HH, Kowalski J., Prionas SD, Allison ACDual role of tumor necrosis factor-α in angiogenesis. Am J Pathol.1992;140:539-544.
19.
Sorbo J., Jakobsson A., Norby K.Mast-cell histamine is angiogenic through receptors for histamine1 and histamine2. Int J Exp Pathol.1994;75:43-50.
20.
McCarthy SA , Kuzu I., Gatter KC, Bicknell R.Heterogeneity of the endothelial cell and its role in organ preference of tumour metastasis. Trends Pharmacol Sci.1991;12:462-467.
21.
Weinstat-Saslow D., Steeg PSAngiogenesis and colonization in the tumor metastatic process: basic and applied advances. FASEB J.1994;8:401-407.
22.
Horak ER, Harris AL, Stuart N., Bicknell R.Angiogenesis in breast cancer: regulations, prognostic aspects, and implications for novel treatment strategies. Ann NY Acad Sci.1993;698:71- 84.
23.
Fox SB, Leek RD, Smith K., Hollyer J., Greenall M., Harris ALTumor angiogenesis in node-negative breast carcinoma-relationship with epidermal growth factor receptor, estrogen receptor, and survival. Breast Cancer Res Treat.1994;29:109-116.
24.
Macchiarini P., Fontanini G., Hardin MJ, Squartini F., Angeletti CARelation of neovascularisation to metastasis of non-small cell lung cancer. Lancet. 1992 ;340:145-146.
25.
Yamazaki K. , Abe S., Takekawa H., et al. Tumor angiogenesis in human lung adenocarcinoma . Cancer.1994;74;2245-2250.
26.
Srivastava A., Laidler P., Davies RP, Horgan K., Hughes LEThe prognostic significance of tumor vascularity in intermediate-thickness (0.76-4.0 mm thick) skin melanoma: a quantitative histologic study. Am J Pathol.1988;133:419-423.
27.
Camochan P. , Briggs JC, Westbury G., Davies Ajs.The vascularity of cutaneous melanoma: a quantitative histologic study of lesions 0.85-1.25 mm in thickness. Br J Cancer.1991;64:102-107.
28.
Barnhill RL , Fandrey K., Levy MA, Mihm MC Jr, Hyman B. Angiogenesis and tumor progression of melanoma. Quantification of vascularity in melanocytic nevi and cutaneous malignant melanoma. Lab Invest. 1992;67:331-337.
29.
Chodak G., Haudenschild C., Gittes RF, Folkman J.Angiogenic activity as a marker of neoplastic and preneoplastic lesions of the human bladder. Ann Surg.1980;192:762-771.
30.
Takahashi A. , Sasaki H., Kim SJ, et al. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res.1994;54:4233-4237.
31.
Wakui S., Masakuni F., Itoh T., et al. Tumour angiogenesis in prostatic carcinoma with and without bone marrow metastasis: a morphometric study. J Pathol. 1992;168:257-262.
32.
Weidner N., Carroll PR, Flax J., Blumenfeld W., Folkman J.Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma . Am J Pathol. 1993;143:401-409.
33.
Li VW, Folkerth RD, Watanabe H., et al. Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumours. Lancet. 1994;344:82-86.
34.
Craft PS, Harris ALClinical prognostic significance of tumour angiogenesis. Ann Oncol.1994;5:305-311.
35.
Gimbrone MA , Leapman SB, Cotran RS, Folkman J.Tumor angiogenesis: iris neovascularization at a distance from experimental intraocular tumors. J Natl Cancer Inst.1973;50:219-228.
36.
Ausprunk DH, Knighton DR, Folkman J.Vascularization of normal and neoplastic tissues grafted to the chick chorioallantois . Am J Pathol. 1975;79: 597-618.
Passaniti A. , Taylor RM, Pili R., et al. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab Invest . 1992;67:519-528.
39.
Jakobsson AEAngiogenesis induced by mast cell secretion in rat peritoneal connective tissue is a process of three phases. Microvasc Res. 1994;47: 252-269.
40.
Pesenti E., Mongelli N., Grandi M., Spreafico F.Suramin prevents neovascularization and tumour through blocking of basic fibroblast growth factor activity. Br J Cancer.1992;66:367-372.
41.
Fett JW, Olson KA, Rybak SMA monoclonal antibody to human angiogenin. Inhibition of ribonucleolytic and angiogenic activities and localization of the antigenic epitope. Biochemistry. 1994;33:5421-5427.
42.
Hori A., Sasada R., Matsutani E., Naito K., Sakura Y., Fujita T., Kozia Y.Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res.1991;51:6180-6184.
43.
Kim KJ, Li B., Winer J., Armanini M., Gillett N., Phillips HS, Ferrara N.Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993;362:841-844.
44.
Arteaga CL, Hurd SD, Winnier AR, Johnson MD, Fendly BM, Forbes JTAnti-transforming growth factor (TGF)-β antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity: implications for a possible role of tumor cell/host TGF-β interactions in human breast cancer progression. J Clin Invest.1993;92:2569 -2576.
45.
Polakowski IJ, Lewis MK, Muthukkaruppan VR, Erdman B., Kubai L., Auerbach R.A ribonuclease inhibitor expresses anti-angiogenic properties and leads to reduced tumor growth in mice. Am J Pathol. 1993;143:507-517.
46.
Rastinejad F., Polverini PJ, Bouck NPRegulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell.1989;56:345-355.
47.
Dameron KM, Volpert OV, Tainsky MA, Bouck N.Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1 . Science1994;265:1582-1584.
48.
O'Reilly MS , Holmgren L., Shing Y., et al. Angiostatin: a novel inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 1994;79:315-328.
49.
Szmurlo A., Marczak M., Jablonska S., Bollag W.Antitumor action of retinoids: inhibition of tumor cell line-induced angiogenesis and prevention of tumors in mice. Dermatology. 1992;184:116-119.
50.
Oikawa T., Ito H., Ashino H., Toi M., Tominaga T., Morita I., Murota S.Radicicol, a microbial cell differentiation modulator, inhibits in vivo angiogenesis . Eur J Pharmacol.1993;241:221-227.
51.
Oikawa T., Okayasu I., Ashino H., Morita I., Murota S., Shudo K.Three novel synthetic retinoids, Re 80, Am 580, Am 80, all exhibit anti-angiogenic activity in vivo. Eur J Pharmacol.1993;249:113-116.
52.
Wright PS, Cross-Doersen D., Miller JA, Jones WD, Bitonti AJInhibition of angiogenesis in vitro and in ovo with an inhibitor of cellular protein kinases, MDL 27032. J Cell Physiol.1992;152:448 - 457.
53.
Sakamoto N. , Iwahana M., Tanaka NG, Osada Y.Inhibition of angiogenesis and tumor growth by a synthetic laminin peptide, CDPGYIGSR-NH2. Cancer Res.1991;51:903-906.
54.
Koch AE, Cho M., Burrows JC, Polverini PJ, Leibovich SJInhibition of production of monocyte/ macrophage-derived angiogenic activity by oxygen free-radical scavengers. Cell Biol Int Rep. 1992;16: 415-424.
55.
Sidky YA, Borden ECInhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular response. Cancer Res.1987 ;47:5155-5161.
56.
Maragoudakis ME, Missirlis E., Karakiulakis GD, Sarmonica M., Bastakis M., Tsopanoglou N.Basement membrane biosynthesis as a target for developing inhibitors of angiogenesis with anti-tumor properties. Kidney Int.1993;43:147-150.
57.
Bastaki M., Missirlis E., Klouras N., Karakiulakis G., Maragoudakis MESuppression of angiogenesis by the antitumor agent titanocene dichloride. Eur J Pharmacol.1994;251:263-269.
58.
Fujimoto J. , Hosoda S., Fujita H., Okada H.Inhibition of tumor angiogenesis activity by medroxyprogesterone acetate in gynecologic malignant tumors. Invasion Metastasis. 1989;9:269-277.
59.
Jikihara H. , Terada N., Yamamoto R., et al. Inhibitory effect of medroxyprogesterone acetate on angiogenesis induced by human endometrial cancer. Am J Obstet Gynecol.1995;167:207-211.
60.
Gadliardi A., Collins DCInhibition of angiogenesis by antiestrogens. Cancer Res.1993;53:533-535.
61.
Maheshwari RK , Srikantan V., Bhartiya D., Kleinman HK, Grant DSDifferential effects of interferon gamma and alpha on in vitro model angiogenesis. J Cell Physiol. 1991;146:164-169.
62.
Cozzolino F. , Torcia M., Aldinucci D., et al. Interleukin 1 is an autocrine regulator of human endothelial cell growth. Proc Natl Acad Sci USA1990;87: 6487-6491.
63.
Voest EE, Kenyon BM, O'Reilly MS, Truitt G., D'Amato RJ, Folkman J.Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst.1995;87:581-586.
64.
DiPietro LA , Nebgen DR, Polverini PJDownregulation of endothelial cell thrombospondin 1 enhances in vitro angiogenesis. J Vasc Res. 1994;31: 178-185.
Merwin JR, Newman W., Beall LD, Tucker A., Madri J.Vascular cells respond differentially to transforming growth factors beta 1 and beta2 in vitro. Am J Pathol.1991;138:37-51.
Yamamoto T. , Sudo K., Fujita T.Significant inhibition of endothelial cell growth in tumor vasculature by an angiogenesis inhibitor, TNP-470 (AGM-1470) . Anticancer Res.1994;14:1-4.
69.
Abe J., Zhou W., Takuwa N., Taguchi J., Kurokawa K., Kumada M., Takuwa Y.A fumagillin derivative angiogenesis inhibitor, AGM-1470, inhibits activation of cyclin-dependent kinases and phosphorylation of retinoblastoma gene product but not protein tyrosyl phosphorylation or protooncogene expression in vascular endothelial cells. Cancer Res.1994;54:3407-3412.
70.
Vukanovic J. , Passaniti A., Hirata T., Traystman RJ, Hartley-Asp B., Isaacs JTAntiangiogenic effects of the quinolone-3-carboxamide linomide. Cancer Res.1993;53:1833-1837.
71.
Borgstrom P. , Torres Filho IP, Vajkoczy P., Strandgarden K., Polacek J., Hartley-Asp B.The quinolone 3-carboxamide linomide inhibits angiogenesis in vivo. Cancer Chemother Pharmacol.1994;34:280-286.
72.
Swain S., Wellstein A., Parker B., Lippman M., Steakley C., DeLap R.Heparin-binding growth factor blockade with pentosan polysulfate. Ann NY Acad Sci.1993;698:63-70.
73.
Nguyen NM, Lehr JE, Pienta KJPentosan inhibits angiogenesis in vitro and suppresses prostate tumor growth in vivo. Anticancer Res.1993;13: 2143-2148.
74.
Maione TE, Gray GS, Petro J., et al. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science. 1990;247:77-79.
75.
Sharpe RJ, Byers HR, Scott CF, Bauer SI, Maione TEGrowth inhibition of murine melanoma and human colon carcinoma by recombinant human platelet factor 4. J Natl Cancer Inst. 1990;82:848 - 853.
76.
Nozaki Y., Hida T., Iinuma S., Ishii T., Sudo K., Muroi M., Kanamarau T.TAN-1120, a new anthracycline with potent angiostatic activity. J Antibiot. 1993; 46:569-579.
77.
Eckhardt SG, Eckardt JR, Weiss G., et al. Phase I assessment of the novel angiogenesis inhibitor DS4152 (tecogalan sodium) [Abstract]. Program and Abstracts of 4th Annual Symposium on Cancer Research in San Antonio1994 ;4:30.
78.
D'Amato RJ, Loughnan MS, Flynn E., Folkman J.Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci.1994;91:4082- 4085.
79.
Herbert JM, Cottineau M., Driot F., Pereillo JM, Maffrand JPActivity of pentosan polysulfate and derived compounds on vascular endothelial cell proliferation and migration induced by acidic and basic FGF in vitro . Biochem Pharmacol.1988;37: 4281-4288.
80.
Zugmaier G. , Lippman ME, Wellstein A.Inhibition by pentosan polysulfate (PPS) of heparin-binding growth factors released from tumor cells and blockage by PPS of tumor growth in animals. J Natl Cancer Inst.1992;84:1716-1724.
81.
Wellstein A. , Zugmaier G., Califano JA, Kern F., Paik S., Lippman METumor growth dependent on Kaposi's sarcoma- derived fibroblast growth factor inhibited by pentosan polysulfate. J Natl Cancer Inst.1991;83:716-720.
82.
Schwartsmann G., Mans Dra, Machado VL, Sander E., Sprinz E., Kalakun L.Phase II study of the basic fibroblast growth factor (β-FGF)-inhibiting agent pentosan polysulfate (PPS) in patients with AIDS-related Kaposi's sarcoma (AIDS-KS). Proc ASCO. 1995;14:290.
83.
Yamaoka M., Yamamoto T., Masaki T., Ikeyama S., Sudo K., Fujita T.Inhibition of tumor growth and metastasis of rodent tumors by angiogenesis inhibitor O-(chloracetyl-carbamoyl) fumagillol (TNP-470 ; AGM-1470). Cancer Res.1993;53:4262-4267.
84.
Tsujimoto H., Hagiwara A., Osaki K., et al. Therapeutic effects of the angiogenesis inhibitor TNP-470 against carcinomatous peritonitis in mice. Anticancer Drugs. 1995;6:438-442.
85.
Takechi A., Uozumi T., Kawamoto K., Ito A., Kurisu K., Sudo K.Inhibitory effects of TNP-470, a new antiangiogenic agent, on the estrogen induced rat pituitary tumors. Anticancer Res.1994;14:157-162.
86.
Yanase T., Tamura M., Fujita K., Kodama S., Tanaka K.Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo. Cancer Res.1993;53:2566-2570.
87.
Yamaoka M., Yamamoto T., Ikeyama S., Sudo K., Fujita T. Angiogenesis inhibitorTNP-470 (AGM-1470) potently inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines. Cancer Res. 1993;53:5233-5236.
88.
Pluda JM, Wyvill K., Figg WD, et al. A phase I study of an angiogenesis inhibitor, TNP-470 (AGM-1470) administered to patients (PTS) with HIV-associated Kaposi's sarcoma (KS) [Abstract] . Proc ASCO.1993;13:51.
89.
Kudelka A., Edwards C., Freedman R., et al. A phase I study of the toxicity, pharmacokinetics, and activity of TNP-470 administered to patients (pts) with advanced or recurrent squamous cell cancer of the cervix. Proc ASCO. 1995 ;14:281.
90.
Burris HAAnticancer agents with unique mechanisms of action. ASCO Educational Book.1993;13: 222-226.
91.
Gill PS, Kidane S., Tulpule A., Espina BM, Masuo K., Sobel RSA phase I study of DS-4152, a novel angiogenesis inhibitor in the treatment of AIDS-related Kaposi's sarcoma [Abstract]. Ann Oncol.1994;5(suppl 5):101.
92.
Fan TDAngiosuppressive therapy for cancer. Trends Pharmacol Sci.1994;15:33-36.
93.
Kahn J., Ruiz R., Kerschmann R., et al. A phase 1/2 study of recombinant platelet factor 4 (rPF4) in patients with AIDS related Kaposi's sarcoma (KS). Proc ASCO . 1993;12:50.
94.
Staddon A., Henry D., Bonnem E.A randomized dose finding study of recombinant platelet factor 4 (rPF4) in cutaneous AIDS-related Kaposi's sarcoma (KS) [Abstract]. Proc ASCO. 1994;13:50.
95.
Northfelt DW , Robles R., Lang W., Wagner B., Kahn J., Bonnem E.Phase 1/2 study of intravenous (IV) recombinant platelet factor 4 (rPF4) in AIDS-related Kaposi's sarcoma (AIDS-KS). Proc ASCO. 1995;14: 288.
96.
Gasparini G. , Harris ALDoes improved control of tumour growth require an anti-cancer therapy targeting both neoplastic and intratumoral endothelial cells?Eur J Cancer. 1994;30A:201-206.
97.
Brem H., Gresser I., Grosfeld J., Folkman J.The combination of antiangiogenic agents to inhibit primary tumor growth and metastasis. J Pediatr Surg.1993;28:1253-1257.
98.
Majewski S. , Szmurlo A., Marczak M., Jablonska S., Bollag W.Synergistic effect of retinoids and interferon a on tumor-induced angiogenesis: anti-angiogenic effect on HPV-harboring tumor-cell lines. Int J Cancer. 1994;57:81-85.
99.
Teicher BA, Sotomayor A., Huang ZDAntiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res.1992;52:6702-6704.
100.
Teicher BA , Holden SA, Ara G., Northey D.Response of the FSaII fibrosarcoma to antiangiogenic modulators plus cytotoxic agents. Anticancer Res.1993;13:2101-2106.
